染色体凝聚2在癌症中的调节作用:超越其在细胞周期中的调节功能。

IF 3.1 Q2 ONCOLOGY
Oncology Reviews Pub Date : 2021-03-19 eCollection Date: 2021-02-26 DOI:10.4081/oncol.2021.525
Ali Calderon-Aparicio, Ann M Bode
{"title":"染色体凝聚2在癌症中的调节作用:超越其在细胞周期中的调节功能。","authors":"Ali Calderon-Aparicio,&nbsp;Ann M Bode","doi":"10.4081/oncol.2021.525","DOIUrl":null,"url":null,"abstract":"<p><p>Regulator of chromosome condensation 2 (RCC2) is an essential protein in order for mitosis to proceed properly. It localizes in the centrosome of chromosomes where is involved in chromosome segregation and cytokinesis. Furthermore, RCC2 associates with integrin networks at the plasma membrane where participates in the control of cell movement. Because of its known role in cell cycle, RCC2 has been linked with cancer progression. Several reports show that RCC2 induces cancer hallmarks, but the mechanisms explaining how RCC2 exerts these roles are widely unknown. Here, we aim to summarize the main findings explaining the roles and mechanisms of RCC2 in cancer promotion. RCC2 is overexpressed in different cancers, including glioblastoma, lung, ovarian, and esophageal which is related to proliferation, migration, invasion promotion <i>in vitro</i> and tumor progression and metastasis <i>in vivo</i>. Besides, RCC2 overexpression induces epithelial-mesenchymal transition and causes poorer prognosis in cancer patients. RCC2 overexpression has also been linked with resistance development to chemotherapy and radiotherapy by inhibiting apoptosis and activating cancer-promoting transcription factors. Unfortunately, not RCC2 inhibitors are currently available for further pre-clinical and clinical assays. Therefore, these findings emphasize the potential use of RCC2 as a targetable biomarker in cancer and highlight the importance for designing RCC2 chemical inhibitors to evaluate its efficacy in animal studies and clinical trials.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2021-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/32/onco-15-1-525.PMC8018209.pdf","citationCount":"1","resultStr":"{\"title\":\"Roles of regulator of chromosome condensation 2 in cancer: Beyond its regulatory function in cell cycle.\",\"authors\":\"Ali Calderon-Aparicio,&nbsp;Ann M Bode\",\"doi\":\"10.4081/oncol.2021.525\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Regulator of chromosome condensation 2 (RCC2) is an essential protein in order for mitosis to proceed properly. It localizes in the centrosome of chromosomes where is involved in chromosome segregation and cytokinesis. Furthermore, RCC2 associates with integrin networks at the plasma membrane where participates in the control of cell movement. Because of its known role in cell cycle, RCC2 has been linked with cancer progression. Several reports show that RCC2 induces cancer hallmarks, but the mechanisms explaining how RCC2 exerts these roles are widely unknown. Here, we aim to summarize the main findings explaining the roles and mechanisms of RCC2 in cancer promotion. RCC2 is overexpressed in different cancers, including glioblastoma, lung, ovarian, and esophageal which is related to proliferation, migration, invasion promotion <i>in vitro</i> and tumor progression and metastasis <i>in vivo</i>. Besides, RCC2 overexpression induces epithelial-mesenchymal transition and causes poorer prognosis in cancer patients. RCC2 overexpression has also been linked with resistance development to chemotherapy and radiotherapy by inhibiting apoptosis and activating cancer-promoting transcription factors. Unfortunately, not RCC2 inhibitors are currently available for further pre-clinical and clinical assays. Therefore, these findings emphasize the potential use of RCC2 as a targetable biomarker in cancer and highlight the importance for designing RCC2 chemical inhibitors to evaluate its efficacy in animal studies and clinical trials.</p>\",\"PeriodicalId\":19487,\"journal\":{\"name\":\"Oncology Reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2021-03-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/32/onco-15-1-525.PMC8018209.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/oncol.2021.525\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/2/26 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/oncol.2021.525","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/26 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

染色体凝聚2调节因子(RCC2)是有丝分裂正常进行所必需的蛋白。它定位于染色体的中心体,参与染色体分离和细胞质分裂。此外,RCC2与质膜上的整合素网络相关,参与细胞运动的控制。由于其在细胞周期中的已知作用,RCC2与癌症进展有关。一些报道表明RCC2诱导癌症特征,但解释RCC2如何发挥这些作用的机制尚不清楚。在这里,我们旨在总结解释RCC2在癌症促进中的作用和机制的主要发现。RCC2在胶质母细胞瘤、肺癌、卵巢癌、食管癌等多种肿瘤中均有过表达,在体外与肿瘤的增殖、迁移、侵袭促进以及体内肿瘤的进展转移有关。此外,RCC2过表达诱导肿瘤患者上皮-间质转化,导致预后较差。RCC2过表达也通过抑制细胞凋亡和激活促癌转录因子与化疗和放疗的耐药发展有关。不幸的是,目前还没有RCC2抑制剂可用于进一步的临床前和临床分析。因此,这些发现强调了RCC2作为癌症靶标生物标志物的潜在用途,并强调了设计RCC2化学抑制剂以评估其在动物研究和临床试验中的有效性的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Roles of regulator of chromosome condensation 2 in cancer: Beyond its regulatory function in cell cycle.

Roles of regulator of chromosome condensation 2 in cancer: Beyond its regulatory function in cell cycle.

Roles of regulator of chromosome condensation 2 in cancer: Beyond its regulatory function in cell cycle.

Roles of regulator of chromosome condensation 2 in cancer: Beyond its regulatory function in cell cycle.

Regulator of chromosome condensation 2 (RCC2) is an essential protein in order for mitosis to proceed properly. It localizes in the centrosome of chromosomes where is involved in chromosome segregation and cytokinesis. Furthermore, RCC2 associates with integrin networks at the plasma membrane where participates in the control of cell movement. Because of its known role in cell cycle, RCC2 has been linked with cancer progression. Several reports show that RCC2 induces cancer hallmarks, but the mechanisms explaining how RCC2 exerts these roles are widely unknown. Here, we aim to summarize the main findings explaining the roles and mechanisms of RCC2 in cancer promotion. RCC2 is overexpressed in different cancers, including glioblastoma, lung, ovarian, and esophageal which is related to proliferation, migration, invasion promotion in vitro and tumor progression and metastasis in vivo. Besides, RCC2 overexpression induces epithelial-mesenchymal transition and causes poorer prognosis in cancer patients. RCC2 overexpression has also been linked with resistance development to chemotherapy and radiotherapy by inhibiting apoptosis and activating cancer-promoting transcription factors. Unfortunately, not RCC2 inhibitors are currently available for further pre-clinical and clinical assays. Therefore, these findings emphasize the potential use of RCC2 as a targetable biomarker in cancer and highlight the importance for designing RCC2 chemical inhibitors to evaluate its efficacy in animal studies and clinical trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncology Reviews
Oncology Reviews ONCOLOGY-
CiteScore
6.30
自引率
0.00%
发文量
9
审稿时长
9 weeks
期刊介绍: Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信